Soligenix's HyBryte Therapy Addresses Critical Gaps in Early-Stage CTCL Treatment

Cutaneous T-cell lymphoma presents clinicians with significant diagnostic challenges in its early stages, creating a difficult treatment landscape for patients. Soligenix Inc. is advancing a novel therapeutic approach through its development of HyBryte, also known as synthetic hypericin, which represents a potential breakthrough for this rare disease. This visible light-activated photodynamic therapy is specifically designed for treating early-stage CTCL and differs fundamentally from traditional ultraviolet-based phototherapies that carry long-term safety risks with cumulative exposure.

HyBryte operates through activation by visible light in the red-yellow spectrum, allowing for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue. Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of this therapy, with regulatory approvals being sought worldwide following successful completion of the second Phase 3 study.

The company's broader development programs include expansion of synthetic hypericin into psoriasis treatment, along with first-in-class innate defense regulator technology for inflammatory diseases. Soligenix's Public Health Solutions business segment focuses on vaccine development programs incorporating proprietary heat stabilization platform technology, supported by government grants and contract funding from agencies including the National Institute of Allergy and Infectious Diseases. For additional information about the company's research and development efforts, visit https://www.Soligenix.com.

NetworkNewsWire serves as a specialized communications platform within the Dynamic Brand Portfolio that delivers financial news and content distribution services. The platform provides access to wire solutions through InvestorWire, article syndication to thousands of outlets, enhanced press release services, and social media distribution to millions of followers. For comprehensive details about their services and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer. The latest updates relating to Soligenix are available through specialized financial news channels that focus on bringing clients unparalleled recognition and brand awareness in today's information-saturated market.